RealWorld Dynamix™: Progressive Forms of MS US 2018 Spotlight II
In the recent RealWorld Dynamix™: Progressive Forms of Multiple Sclerosis (US) patient chart audit (n=755 patients), Genentech’s Ocrevus was a common alternative or “back up” disease-modifying therapy (DMT) for secondary progressive multiple sclerosis (SPMS) patients that went on to be treated with a different DMT. Competition within the SPMS patient segment may soon increase substantially with a March 2019 PDUFA date anticipated for Novartis’ Mayzent (siponimod), currently under review for a first-in-market SPMS label. Based upon Spherix’s audit data, Mayzent, if approved, would appear to represent a greater competitive switch threat to Ocrevus within the active compared to the not active SPMS segment. See complimentary highlights from the full report below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.